News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Proteome Sciences PLC (PRM.L) Release: Settlement of Warranty Claim Against Sanofi-Aventis Deutschland GmbH


9/30/2010 11:40:40 AM

28 September 2010, London UK – Proteome Sciences plc filed a court claim for the breach of certain contractual and statutory obligations of Sanofi-Aventis Deutschland GmbH arising from or in connection with the Agreement of Sale and Transfer concerning a Share in Xzillion Proteomics Vewaltungs GmbH and concerning a Limited Partnership Interest in Xzillion Proteomics GmbH & Co. KG of 4 July 2002.

A settlement has been reached between the parties under which a payment of ?11m will be received by Proteome Sciences by the close of business on 29 September 2010. Further details of the settlement have not been disclosed due to the confidentiality clause forming part of the settlement.

For further information please contact:

Proteome Sciences plc www.proteomics.com Tel: +44 (0)1932 865065 Christopher Pearce, Chief Executive Officer christopher.pearce@proteomics.com James Malthouse, Finance Director james.malthouse@proteomics.com Dr. Ian Pike, Chief Operating Officer ian.pike@proteomics.com

Nominated Adviser Singer Capital Markets Limited Shaun Dobson/Claes Spång Tel: +44 (0)20 3205 7500

Public Relations IKON Associates Redleaf Communications Limited Adrian Shaw Anna Dunkin/Lucy Salaman Tel: +44 (0)1483 271291 Tel: +44 (0)20 7566 6700 Mobile: +44 (0)7979 900733 Email: proteome@redleafpr.com Email: adrian@ikonassociates.com

About Proteome Sciences

Proteome Sciences is a global leader in applied proteomics and uses high sensitivity proprietary technologies for protein biomarker discovery, validation and assay development. The Company’s own research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers, including Alzheimer’s disease, stroke, brain damage and lung cancer for diagnostic and treatment applications. These biomarkers are available for outlicensing. The first blood test for lung cancer using Proteome Sciences’ biomarkers was launched in the USA in 2009 and received Medicare reimbursement in 2010. Its PS Biomarker Services provides ISO 9001: 2008 accredited facilities in Frankfurt, Germany, using proprietary isobaric and isotopic Tandem Mass Tags® (TMT®) to discover protein biomarkers, and reference materials combined with isotope dilution mass spectrometry. Highly multiplexed assays can be developed rapidly and are suitable for screening hundreds of candidate biomarkers in validation studies. Assays for validated biomarkers can be transferred for immunoassay development. Proteome Sciences, based in Cobham, UK, has facilities in London and Frankfurt and delivers outsourced proteomics services and proprietary biomarkers to pharmaceutical, biotechnology and diagnostics companies. Visit http://www.proteomics.com.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES